Advancing Disease-Modifying Pulmonary Fibrosis Drugs

Welcome To the Go-To Industry Forum for Pulmonary Fibrosis Professionals

The pulmonary fibrosis field is entering a pivotal moment. Boehringer Ingelheim’s positive Phase 3 trials for nerandomilast, poised to be the first new approval in over a decade, have injected long-awaited momentum into the space. PureTech Health, Endeavor BioMedicines, Insilico Medicine, Bristol Myers Squibb, and United Therapeutics are rapidly advancing through mid- to late-stage trials, signaling a renewed era of therapeutic possibility. Yet 2025 has also brought setbacks, including Pliant’s discontinuation of the BEACON-IPF study for bexotegrast due to safety concerns, underscoring the complexity of treating this disease.

If ever there was a year to invest in this space, it’s now. This August, meet your global community, spanning discovery, preclinical, translational, and clinical development, at the only industry-focused summit dedicated to pulmonary fibrosis. Gain the full spectrum of insight needed to bring better drugs to patients, faster.

Complete scope of work from concepts to clinical development and possibly approval. Excellent personal interaction with academics and biotechnology company representatives.

JN Nova Pharmaceuticals

JN Pharma Bio

Fantastic meeting overall! Very helpful for someone like me who is just entering the IPF field, especially the workshops. I appreciate the separation between preclinical and clinical tracks. Enjoyed the open discussions during the workshops and expert panels.

University of Massachusetts Medical School

Screenshot 2025-04-23 155332

The networking was very valuable, and I learned a lot about the field. The scientific content of the talks was well balanced.

Daiichi Sankyo

Daiichi Sankyo

Explore the Full Event Guide

  • 35+ Expert Speakers
  • 3 Days of Unmissable Data-Driven Content
  • Brand-New Probing Seminar Afternoon
  • 4 Deep Dive Discussion-Based Workshops
  • All at the Only Industry-Based Drug Development Summit
Copy of 60265 - Brochure Image (1)

What To Expect

150+

Global Attendees from Across the Pulmonary Fibrosis Landscape

40+

Expert Speakers with Unique Insights

10+

Hours of New & Improved Face-to-Face Networking Opportunities

2

Dedicated Tracks of Content for the Whole Team

1

Brand-New Probing ‘Setbacks to Solutions’ Seminar Afternoon

4

Unmissable Deep Dive Workshops with Industry Leaders

5

World Renowned Academic KOL’s

Official Partners

Copy of 60265 - Brochure Image

Attending Companies Include

Explore Related Events

IPFsummit-66
Explore the Agenda

Hear the latest industry breakthroughs and gain exclusive regulatory insights during our packed agenda, interactive roundtables, and new CXOs’ panel discussion.

IPFsummit-213
Partner With Us

Position yourself alongside other leading solution providers to ensure your brand is at the heart of biopharma deals.

IPFsummit-274
Join Biopharma Experts

Be part of the hottest conversations with like-minded attendees spanning all stages of drug development and make critical connections during our dedicated networking sessions.